Skip to Main Content

Author Details

Wolfgang Lilleby
Oslo University Hospital
1999
74
18
PMIDPaper TitleJournal TitlePublished Year
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36715014Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.Int J Cancer2023
34762317Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.Prostate2022
35613827Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.J Immunother Cancer2022
35463376A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.Front Oncol2022
35813256Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer.Eur Urol Open Sci2022
36353660Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer.Eur Urol Open Sci2022
34990726Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.Radiother Oncol2022
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
33096165Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival.Radiother Oncol2021
33648662<sup>18</sup>F-Fluciclovine PET for Assessment of Prostate Cancer with Histopathology as Reference Standard: A Systematic Review.PET Clin2021
33648661Prostate-Specific Membrane Antigen PET for Assessment of Primary and Recurrent Prostate Cancer with Histopathology as Reference Standard: A Systematic Review and Meta-Analysis.PET Clin2021
33868933Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up.Urol Case Rep2021
33922147The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology.J Pers Med2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34206815Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer.J Pers Med2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
30992160Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.Eur Urol2020
34337468Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.Eur Urol Open Sci2020
33258482Impact of radiation dose on recurrence in high-risk prostate cancer patients.Prostate2020
33276562Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy.Cancers (Basel)2020
32199872Local Recurrence of Prostate Cancer to the Intersphincteric Space: A Case Report.Urology2020
30446451Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.Urol Oncol2019
31453108Metastatic-directed therapy using PSMA-PET/CT at PSA relapse.Urol Case Rep2019
30888866<i>PTEN</i> Expression in Prostate Cancer: Relationship With Clinicopathologic Features and Multiparametric MRI Findings.AJR Am J Roentgenol2019
30379559Localization of radio-recurrence within the prostate: anti-3-18F-FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.Acta Radiol2019
30389241Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.Radiother Oncol2019
29509865Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.JAMA2018
29976500Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.Int J Radiat Oncol Biol Phys2018
27406859Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.Clin Nutr2017
28391357Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.Cancer Immunol Immunother2017
26959297Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.Acta Oncol2016
25806763Low-dose-rate brachytherapy for low-grade prostate cancer.Tidsskr Nor Laegeforen2015
26654961Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report.J Med Case Rep2015
26577452Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.Radiat Oncol2015
26080763[Re: The problematical prostate cancer].Tidsskr Nor Laegeforen2015
26130530[Re: Different guidelines for treatment of prostate cancer].Tidsskr Nor Laegeforen2015
25927504Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.Acta Oncol2015
24844918Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.Acta Oncol2014
22341412Bother problems in prostate cancer patients after curative treatment.Urol Oncol2013
24035332Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.Int J Radiat Oncol Biol Phys2013
23532709Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.Prostate2013
23280694Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients.Int J Cancer2013
21936756Detection of prostate cancer relapse with PET/CT using a novel radiotracer.Acta Oncol2012
22138456Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.Int J Radiat Oncol Biol Phys2012
21809351Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones.Prostate2012
20586661Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center.Acta Oncol2011
21134733Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.Clin Oncol (R Coll Radiol)2011
19247406[Incorrect about hormone treatment in prostatic cancer].Tidsskr Nor Laegeforen2009
  • 1 - 50 of 74

Recommended Authors

Ryan Phillips
Johns Hopkins University
Career Start Year 2017
Number of shared co-authors 21
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 38
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 15
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 14
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 3
John Thoms
Memorial University
Career Start Year 2008
Number of shared co-authors 3
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 5
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 18
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 4
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 28
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 28
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 29
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 4
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 18
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 22
Laurence Collette
Belgium International Drug Development Institute
Career Start Year 1995
Number of shared co-authors 17
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 21
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 8
Markus Graefen
University Hospital Frankfurt, Goethe University Frankfurt am Main
Career Start Year 1993
Number of shared co-authors 16
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 27
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 16
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 14
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 42
Oliver Sartor
Tulane University School of Medicine
Career Start Year 1983
Number of shared co-authors 27
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 20
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 16
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 44
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 14
Michel Bolla
universite Grenoble-Alpes (UGA)
Career Start Year 1971
Number of shared co-authors 29
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 26

Collaborators

Amar U Kishan
University of California los angeles
Co-authored papers 12
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 12
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 10
Trude B Wedde
Oslo University Hospital
Co-authored papers 9
Michael L Steinberg
University of California los angeles
Co-authored papers 9
Jay P Ciezki
Cleveland Clinic
Co-authored papers 8
Ryan Fiano
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 8
Daniel J Krauss
William Beaumont School of Medicine
Co-authored papers 8
Gregory S Merrick
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 8
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 8
Richard G Stock
Icahn School of Medicine at Mount Sinai
Co-authored papers 8
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 8
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 8
Eyad Abu-Isa
Ascension Providence Hospital
Co-authored papers 8
Curtiland Deville
Johns Hopkins University
Co-authored papers 8
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 8
David Jeffrey Demanes
University of California los angeles
Co-authored papers 8
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 8
Chandana A Reddy
Cleveland Clinic
Co-authored papers 8
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 8
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 7
Ashley E Ross
Northwestern University
Co-authored papers 7
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 7
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 7
Jahn M Nesland
The Norwegian Radium Hospital, Oslo University Hospital
Co-authored papers 6
Eric A Klein
Cleveland Clinic
Co-authored papers 6
Ridwan Alam
Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 5
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 5
Avinash Pilar
Princess Margaret Cancer Centre, University of Toronto
Co-authored papers 5
Release 1.2